Fig. 4: The combination of CX-5461 and topotecan does not result in enhanced replication fork degradation or DNA strand break generation. | British Journal of Cancer

Fig. 4: The combination of CX-5461 and topotecan does not result in enhanced replication fork degradation or DNA strand break generation.

From: The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer

Fig. 4

a–e OVCAR4 cells were treated with 1 μM CX-5461, 20 nM topotecan, CX-5461 and topotecan or 1 μM doxorubicin (as indicated) for 3 h. a Representative images and quantification of decreased IdU to CldU ratio is represented as median with interquartile range and statistical significance was determined by Kruskal–Wallis one-way ANOVA (****P < 0.0001). b Representative images and c quantification of foci number for γH2AX. Cells were stained for EdU and DAPI to label replicating cells and nuclei, respectively. Scale bar is 20 μm. Data are presented as median with interquartile range and statistical significance for increased foci per cell was determined by Kruskal–Wallis one-way ANOVA (*P < 0.05; ***P < 0.001, ****P < 0.0001). d Representative images and e quantification of alkaline comet assay is presented as median with interquartile range and statistical significance was determined by Kruskal–Wallis one-way ANOVA (**P < 0.01; ****P < 0.0001 from n = 3 experiments).

Back to article page